<DOC>
	<DOCNO>NCT02275351</DOCNO>
	<brief_summary>The purpose study characterize safety , tolerability , efficacy topical SM04554 solution ( 0.15 % 0.25 % ) apply scalp male subject Androgenetic Alopecia ( AGA ) .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Efficacy Topical SM04554 Solution Male Subjects With Androgenetic Alopecia ( AGA )</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Clinical diagnosis AGA Willing inform female , may interact , use topical investigational product direct contact avoid potential harm fetus unknown Willing maintain hair style study start duration study Willing use semipermanent hair product ( e.g. , color , texturizers , relaxer ) duration study . Daily style product allow ( e.g. , hair gel , mousse , style spray ) . Willing use mild nonmedicated shampoo conditioner duration study Willing receive small scalp tattoo Able read understand English Clinical diagnosis alopecia areata nonAGA form alopecia Scalp hair loss treatment area , due disease , injury , medical therapy Males sexually active partner capable become pregnant , neither surgery become sterilize , use effective method birth control willing use effective method birth control study treatment period 90 day post last dose study medication Current skin disease ( e.g. , psoriasis , atopic dermatitis , skin cancer , eczema , sun damage , seborrheic dermatitis ) , cut and/or abrasion scalp condition ( e.g. , sunburn , tattoo ) treatment area , opinion Investigator , might put subject risk interfere study conduct evaluation History surgical correction hair loss scalp Previous exposure SM04554 Use product device purport promote scalp hair growth ( e.g. , finasteride minoxidil ) within 24 week prior study start Use antiandrogenic therapy ( e.g. , spironolactone , flutamide , cyproterone acetate , cimetidine ) within 12 week prior study start History hair transplant Current use occlusive wig , hair extension , hair weave Participation investigational drug medical device trial , include administration investigational study medication medical device , within 30 day 5 halflives investigational agent , whichever longer , prior study start Subjects history clinically significant cardiac arrhythmia determine Investigator Subjects clinically significant finding medical history , clinical laboratory test , electrocardiogram ( ECG ) , vital sign , opinion Investigator , could interfere objective study put subject risk Subjects unwilling refrain sperm donation study treatment period 90 day post last dose study medication Subjects pregnant partner study start Use semipermanent hair product ( e.g. , color , texturizers , relaxer ) within 30 day prior study start Use medicate shampoo conditioner within 30 day prior study start</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>alopecia</keyword>
	<keyword>topical</keyword>
	<keyword>Samumed</keyword>
</DOC>